Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I feel different!
More news are coming.
Start buying now while it's at this price!
Hi Wildo
How are you?
Looke like Hawaii is closer than I was expecting!
FN
Sorry! I didn't see the date of your article! May 2004
Forget about my last post!
FN
That may be why the Berlin stock went to $80.00?
leifmith,
Thank you for taking the time to post Patrick Cox press release.
Very well written and easy to understand.
NNVC is not yet very well known.
We need 10 people like Mr. Cox to increase advertising on NNVC.
Anyways, more great news are coming!
Thank you.
FN
Leifmith,
Thank you for the update.
Can you let us know what did he said?
Thank you for the information.
FN
Yes the board need us!!!
And I feel good about our future.
We are close to success!!!
Ho yes !!!
Green is my favorite color !!!
Forza NNVC !!!!!!
Yes you will.
It was a great surprise to meet Dr Seymour and his wife !
I am also looking forward to meeting
you!
All the best!
FN
Yes, This is the time!
Like you said other big news are coming.
Don't miss it !!!
This is big!!!
FN
I'm so agree with you Weedie!
Those are great news.
Yes, it was, but it looked great!
Thank you Wendy.
Tha Forze is with me and NNVC !!!!!!!!!!!!!!
WOW NANOVIRICIDES EUROPE BERLIN NV3.BE WENT FROM 0.42 TO 20.44
How that could be possible ??????
http://finance.yahoo.com/q?s=NV3.BE
The flu season in Australia is in May.
In Europe the flu is inJanuary.
That maybe why they chose Australia for next year.
Bad advice!
At this price, you want to buy!
Echo,
Yes I agree but I think the company has other plans.
FORZANANNO.
Happy fourth of July Echo!
And yes, NNVC will be at $4.00.
Wid4nano
Bravissimo !!!
Forza NNVC !!!!!!!!!!!!!
UP! UP! UP!
GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO NNVC !!!!!!!!
That's funny!!!
Hey Weedie,
I didn't have time to respond to your message, I had to go to work.
I am doing good thank you.
I hope everything is fine with you and you are doing better!
We are thankful to have you on that board !
FN
Got to go to work!
He He He, I am "The Forze" Big "NNVC" HERO!!!
Show must go on !!!!
FORZA NNVC !!!!
I am here Weedie!
How are you doing with your knee?
Gary is right, you're like the Bionic Woman Jaime Sommers.
You're going to dance and jump with a superhuman speed.
You will speed NNVC to pass the FDA wit his 9 viruses.
GOOOOOO SUPER WEEDIE GOOOOOOOOOOO NNVC !!!!!!!!!!
Happy easter!
Thank you to you all for your kind comments.
Now we know that we are almost there!
Hi every one,
This morning I had great news from Dr. Seymour.
I'm sorry if I did not get them to you earlier.
Had the meeting with the FDA.
They will provide us with a written summary.
We will seek permission to share that information.
After all these years, we can finally focus on getting FluCide into humans as quickly as possible.
EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics
http://www.nanoviricides.com
eugene@nanoviricides.com
310-486-5677
I cross my fingers for you! Keep me posted!
I would love to visit your area.
It must be very beautiful.
FN
Yes it's true, we had a great time.
Let me know If you come to Los Angeles.
I'm glad everything is working out for you.
Lorenzo
Hey Kelt, it's always good to hear from you!
Cherry and I are very pleased to have received David (Wild4Nano) and his wife at home.
David is exactly as I imagined.
We're very fortunate to have him on the board, he's a brilliant man!
I introduce them the Prosecco. a delicious Italian sparkling white wine that unlike the champagne does not give you any headache the next day.
I hope to find some Prosecco in Hawaii to celebrate our victory!
Cheers !!!!
FN
It's good to have you back Weedie!
The board needs your positive energy!
Wow!!!! $0.90
Why not $1.00 ...
Wild4nano,
I cannot wait to meet you !!!!
I must say that thanks to NNVC we formed a group of friends.
Abbam
I cannot answer you in private.
I'm as surprised as you! I do not know why the stock drops.
But I believe in this company.
Yes we will !!!
The Company has received a new financing from Seaside.
NanoViricides Completes a $5 Million Raise in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that it has received the final tranche of $2.5M from Seaside 88, LP (“Seaside”), thereby completing the total of $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on November 3, 2011. This financing draws down on the Company’s previously announced universal registered shelf “Form S-3” offering. The registered shelf offering became effective on April 29, 2010 and continues to remain effective. There are no warrants associated with this raise.
The Company has continued to keep its expenditure rate low, while advancing its Influenza therapeutics program, FluCide™ towards an IND filing with the US FDA. The Company has recently filed a request letter for a pre-IND Meeting with the US FDA and subsequently submitted a pre-IND dataset on its flagship FluCide clinical candidate, NV-INF-1, to the US FDA. The Company intends to seek two different indications for this treatment: (1) out-patient influenza, and (2) hospitalized patients presenting with influenza-like illness (ILI).
The Company believes that this single anti-influenza drug should be effective against most forms of Influenza A, including H5N1 Bird Flu, Highly Pathogenic Avian Influenzas (HPAI), Epidemic influenzas (such as the “swine flu” 2009/H1N1/A), and seasonal influenzas.
The Company has received this current financing from a single investor, Seaside 88, LP (“Seaside”), a Florida limited partnership. Seaside has, to date, financed NanoViricides with a total of approximately $20 million under a similar arrangement to the financing now completed.
“We continue to have more than 24 months of cash in hand, based on our current rate of expenditure, with this additional raise. We now have sufficient cash in hand to be able to complete our pre-IND studies on FluCide and file an IND in due course,” said Eugene Seymour, MD, MPH, CEO of the Company.
In addition, the Company has continued its progress in the pre-clinical programs against several other diseases. In particular, the Company has announced that it has developed an anti-HIV ligand that was substantially superior to the earlier anti-HIV ligands employed by the Company. The Company is also optimizing its anti-Herpes drug candidates, its External Eye anti-viral drug candidates, as well as its Dengue therapeutic candidates. The Company has a very broad pipeline, based on its novel “nanoviricide®” platform technology.
On November 2, 2011, NanoViricides had entered into a securities purchase agreement with Seaside for the purchase and sale of up to 500,000 shares of its Series B Preferred Stock at the purchase price of $10.00 per share. Seaside purchased an initial 250,000 shares of the Company’s Series B Preferred Stock at the purchase price of $10.00 per share for an aggregate purchase price of $2,500,000 (the “initial tranche”) on the same date. The Company thereby had received $2.5M upon closing, with a net of approximately $2.32M after deducting brokerage commission and expenses. The conversion of these $2.5M worth of Series B Preferred stock to common stock was completed on January 24, 2012. Following this conversion completion, on February 8, 2012, Seaside exercised its option to purchase an additional 250,000 shares of the Company’s Series B preferred stock on identical terms (the “final tranche”). The Company received $2.5M upon this final closing, with a net of approximately $2.32M after deducting brokerage commission and expenses. In addition, on February 8, 2012, $400,000 of Series B Preferred stock was converted to the Company’s common stock. Additional conversions will follow every fourteen days. At each conversion, 40,000 shares of the Series B Preferred Stock purchased by Seaside will be automatically converted into common stock using a conversion factor calculated as follows. The conversion factor shall equal the purchase price of $10 per share of the preferred stock, divided by the lesser of (i) the ten day daily volume weighted average of actual trading prices (“VWAP”) of the common stock multiplied by 0.85; or (ii) the VWAP for the trading day immediately prior to a conversion date multiplied by 0.88. In addition, the unconverted shares of the Series B Preferred Stock will accrue a dividend at a 10% annualized rate. The accrued dividend shall be payable in common stock at the time of each conversion. The Company does not pay a dividend on the shares of its common stock or the shares of its Preferred Series A stock, and will not be able to pay any dividend on these securities while any shares of the Series B Preferred stock remain unconverted. The shares of Series B Preferred Stock and the shares of common stock underlying the Series B Preferred Stock and the dividend earned on it were offered pursuant to an effective shelf registration statement. The Series B Preferred Stock does not have any voting rights except as set forth in the Certificate of Designation, as amended, creating the stock.
Midtown Partners & Co., LLC, acted as the placement agent for this transaction. Midtown received a cash placement fee of 6%.
A shelf registration statement relating to the shares of common stock underlying the shares of preferred stock issued in the offering has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. A prospectus supplement relating to the current transaction has been filed by NanoViricides with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from NanoViricides by contacting NanoViricides, Inc., 135 Wood Street, Suite 205, West Haven, Connecticut 06516. This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of preferred or common stock of NanoViricides. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
finance.yahoo.com/q?s=NNVC.OB
I'm with you in spirit.
And I pray the good Lord for your mom.
Lorenzo
Yes, the fact of meeting him reassure me about NNVC.
Now it's a matter of time before NanoViricides is known worldwide.